Cell‐free DNA as a biomarker of aging

Teo, Yee Voan; Capri, Miriam; Morsiani, Cristina; Pizza, G; Faria, Ana Maria Caetano; Franceschi, Claudio; Neretti, Nicola

doi:10.1111/acel.12890

Cited by 94 publications

(90 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, growing evidence shows that TERT is protective in the microcirculation against prolonged vascular stress [7,8]. Among the different biomarkers proposed, including cell-free DNA and circulating extracellular RNAs [9,10], growth differentiation factor (GDF-15) appears particularly promising due to the ease of collecting specimens and the low costs. However, little is known about how serum GDF-15 changes with age.…”

Section: Introductionmentioning

confidence: 99%

GDF-15 as a biomarker of aging

Liu

Huang

Lyu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The aging process is accompanied by the gradual development of chronic systemic inflammation (inflamm-aging). Growth differentiation factor-15 (GDF-15) is associated with inflammation and known to be a stress-induced factor. The present study aimed to explore the association of GDF-15 with aging.Methods: In this cross-sectional study, serum GDF-15, hematological parameters, and biomedical parameters were determined in 120 healthy individuals (23-83 years old, males). Three telomere related parameters, including telomere length, telomerase activity, and the expression of human telomerase reverse transcriptase (hTERT) mRNA were also quantified.Results: The older group has a higher levels of GDF-15 and lower expression of hTERT mRNA, and PBMC telomerase activity (p<0.001). In individuals with high GDF-15 levels, they were older, and presented with the lower level of hTERT mRNA and T/S ratio (p<0.01). Spearman correlation analysis shows that GDF-15 positively correlated with age (r=0.664, p<0.001), and negatively correlated with telomere length (r=-0.434, p<0.001), telomerase activity (r=-0.231, p=0.012), and hTERT mRNA (r=-0.206, p=0.024). Furthermore, in multivariate regression analysis, GDF-15 levels showed a statistically significant linear and negative relationship with PBMC telomerase activity (β-coefficient=-0.583, 95% CI -1.044 to -0.122, p=0.014), telomere length (β-coefficient=-0.200, 95% CI -0.305 to -0.094, p<0.001), and hTERT mRNA (β-coefficient=-0.207, 95% CI -0.312 to -0.102, p<0.001) after adjusting for confounders.Conclusions: In conclusion, our results show that circulating GDF-15 is the potential biomarkers of aging that may influence the risk and progression of multiple aging conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

GDF-15 as a biomarker of aging

Liu

Huang

Lyu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, the distribution of fragment length in stroke patients is still unclear. Recently, researchers had revealed that the distribution of nucleosome spacing displayed regularity in the healthy group, whereas aberrant nucleosome spacing could be detected in many diseases [26][27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

The Length and Distribution of Plasma Cell-Free DNA Fragments in Stroke Patients

Cui

Du²,

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

A number of studies have shown that plasma cell-free DNA is closely related to the risk of stroke, but the fragmentation status of plasma cell-free DNA and its clinical application value in ischemic stroke are still unclear. In this study, 48 patients with new ischemic stroke and 20 healthy subjects were enrolled. The second-generation high-throughput sequencing technique was used to study the plasma cell-free fragment length and regional distribution of the subjects. As noted in our results, the ratio of plasma cell-free DNA fragments in the disease group was significantly greater than that of the healthy group in the 300–400 bp range; conversely for fragments at the 75–250 bp range, the ratio of plasma cell-free DNA fragments in the patient group was apparently lower than that of the healthy group. In-depth analysis of the proportion of fragments distributed on each component of the genome was carried out. Our results recorded that the plasma cell-free DNA fragments in the disease group were inclined to the EXON, CpG islands, and ALU regions in contrast to that of the healthy group. In particular, fragments within the 300–400 bp range of the disease group were enrichment in the regions of EXON, INTRON, INTERGENIC, LINE, Fragile, ALU, and CpG islands. In summary, our findings suggested that the intracellular DNA degradation profiles could be applied to distinguish the stroke group and the healthy group, which provided a theoretical basis for the clinical diagnosis and prognosis of stroke by profiling the characteristic of plasma cell-free DNA fragments.

show abstract

“…Teo et al showed a remarkable consistency between nucleosome signals of cfDNA and redistribution of heterochromatin, which has a role in cellular senescence and aging. In this perspective, cfDNA may be designated as a biomarker of age or a predictor of health status (14).…”

Section: Discussionmentioning

confidence: 99%

The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant-related Complications in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Yeğin¹,

Can²,

Gökçen³

et al. 2020

Balkan Med J

View full text Add to dashboard Cite

Background: Cell-free DNA, which may be considered as "liquid" biopsy, may serve as a diagnostic and prognostic marker not only in hematological malignancies but in solid tumors as well. Aims: To investigate the prognostic role of pre-transplant cell-free DNA levels in allogeneic hematopoietic stem cell transplant recipients. Study Design: Retrospective cohort study. Methods: A total of 177 allogeneic hematopoietic stem cell transplant recipients [median age: 36 (16-66) years; male/female: 111/66] with an initial diagnosis of acute leukemia were included in the study. Cell-free DNA was extracted from pre-transplant serum samples by using the MagNA Pure Compact Nucleic Acid Isolation Kit I with the MagNA Pure Compact instrument (Roche Diagnostics, Penzberg, Germany). Results: A positive correlation was demonstrated between cell-free DNA and age (p=0.018; r=0.177). Pre-transplant cell-free DNA levels were lower in bcr-abl (+) patients (p=0.001), while an adverse correlation was indicated between cell-free DNA and bcr-abl levels (p=0.001; r=−0.531). Acute lymphoblastic leukemia patients with bcr-abl positivity (p=0.001) or abnormal cytogenetics (p=0.038) represented significantly lower pre-transplant cell-free DNA levels. Cell-free DNA levels were lower in patients who developed sinusoidal obstruction syndrome (p=0.035). In terms of long-term complications, acute myeloid leukemia patients who experienced post-transplant relapse had significantly lower pre-transplant cell-free DNA levels (p=0.024). Overall survival was not statistically different between high-and low-cell-free DNA groups (45.2% vs 22.5; p=0.821). Conclusion: In general, low serum levels of pre-transplant çellfree DNA seem to be associated with transplant-related morbidities and may be considered an adverse prognostic factor for allogeneic hematopoietic stem cell transplant recipients.

show abstract

Cell‐free DNA as a biomarker of aging

Cited by 94 publications

References 65 publications

GDF-15 as a biomarker of aging

GDF-15 as a biomarker of aging

The Length and Distribution of Plasma Cell-Free DNA Fragments in Stroke Patients

The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant-related Complications in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Contact Info

Product

Resources

About